Silence Therapeutics has been granted a patent for nucleic acid products that can inhibit target gene expression. The invention involves duplex regions with specific nucleotide lengths and structures to interfere with RNA transcribed from the target gene. This innovation opens up new possibilities for therapeutic applications. GlobalData’s report on Silence Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Silence Therapeutics, was a key innovation area identified from patents. Silence Therapeutics's grant share as of May 2024 was 40%. Grant share is based on the ratio of number of grants to total number of patents.
Nucleic acid for inhibiting target gene expression
A recently granted patent (Publication Number: US11987794B2) discloses a nucleic acid designed to inhibit the expression of a target gene in a cell. The nucleic acid consists of at least one duplex region with specific characteristics, including the length of the strands, the presence of inverted nucleotides at the ends, and potential modifications such as 2'-O-methyl or 2'-F modifications. Additionally, the nucleic acid may be conjugated to a ligand, enhancing its targeted delivery to specific cells or tissues.
Furthermore, the patent claims cover various embodiments of the nucleic acid, including modifications to the nucleotides, the presence of specific ligands like GalNac, and the composition of the nucleic acid with a physiologically acceptable excipient for therapeutic use. The patent also extends to methods of treating diseases or disorders by administering the nucleic acid composition to individuals in need of treatment. Overall, the patent highlights the innovative design and potential therapeutic applications of the nucleic acid molecule in gene expression regulation and disease treatment.
To know more about GlobalData’s detailed insights on Silence Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
